Search clinical trials for: AMT-191

Total 6513 results

UniQure Biopharma B.V.

Recruiting

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

Fabry Disease

United States
Applied Molecular Transport

Active, not recruiting

Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)

Ulcerative Colitis

United States, Hungary, Ukraine, Germany, United Kingdom, Belarus, Bulgaria, Canada, France, Georgia, Moldova, Republic of, Poland, Russian Federation, Switzerland
Applied Molecular Transport

Completed

Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis (FILLMORE)

Pouchitis

United States, Canada, France, Spain, United Kingdom, Germany, Belgium, Hungary, Netherlands, Switzerland
Chang Gung Memorial Hospital

Completed

Comparison of Choosing Free ALT or Free PMT for Reconstruction With Head and Neck Cancer

Head and Neck Cancer | Reconstructive Surgery

Taiwan
AbbVie
Genentech, Inc.; Amgen

Terminated

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

Acute Myeloid Leukemia | Non-Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma

United States, Australia, Germany
Applied Molecular Transport

Completed

SAD/MAD Study in Healthy Subjects and Adults With UC to Evaluate Safety, Tolerability, PK, PD of AMT-101 (AURIGA1)

Ulcerative Colitis

Germany, Georgia, Moldova, Republic of, Ukraine
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | CD20 Positive | Refractory Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | CCND1 Protein Overexpression | CD5 Positive | FCER2 Negative | Pleomorphic Variant Mantle Cell Lymphoma | t(11;14)(q13;q32)

United States
Amgen

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

United States, Australia, New Zealand
Ludwig Institute for Cancer Research
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen

Neoplasms

Australia
Multitude Therapeutics Inc.
Tigermed Consulting Co., Ltd

Recruiting

AMT-151 in Patients With Selected Advanced Solid Tumours

Ovarian Cancer | Ovarian Epithelial Cancer | Lung Adenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Endometrial Cancer | Advanced Cancer | Ovarian Clear Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial... and other conditions

China, Australia
Amgen

Terminated

Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

Obesity

United States
Amgen

Terminated

Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

MUC17-positive Solid Tumors

United States, Korea, Republic of, Taiwan, Spain, Austria, France, Japan, Germany, Netherlands
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, Canada, Denmark, Italy, Hungary, Germany, Switzerland, Netherlands, Australia, Russian Federation, Austria, France, United Kingdom, Czechia, Greece, Poland, Estonia, Latvia, Norway
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Canada, Denmark, Belgium, Hungary, Switzerland, Netherlands, Austria, Czechia, France, United Kingdom, Germany
Amgen

Recruiting

A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

MTAP-null Non-Small-Cell Lung Cancer | MTAP-null Solid Tumors

United States, Australia
Anbogen Therapeutics, Inc.

Recruiting

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Non Small Cell Lung Cancer | Advanced Solid Tumor | HER2 Mutations

Taiwan
Amgen

Terminated

Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects

Diabetes Mellitus

United States
Amyndas Pharmaceuticals S.A.

Completed

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

Complement Mediated Diseases

United States
AbbVie
Genentech, Inc.

Completed

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

Chronic Lymphocytic Leukemia | 17p Deletion | Cancer of the Blood and Bone Marrow

United States, Australia, Canada, France, Germany, Poland, United Kingdom
Amgen

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Crohn's Disease | Ulcerative Colitis

United States, Australia
AbbVie
Genentech, Inc.

Completed

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

Acute Myeloid Leukemia | AML | Acute Myelogenous Leukemia
Research Foundation for Mental Hygiene, Inc.

Completed

Attention-Bias Modification Treatment for PTSD

Posttraumatic Stress Disorder (PTSD)

United States
Amytrx Therapeutics, Inc.
Amarex Clinical Research

Completed

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Fred Hutchinson Cancer Center
AstraZeneca

Recruiting

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Miguel Monfort Montolio

Not yet recruiting

Efficacy of Animal-assisted Therapy in Patients With Borderline Personality Disorder and Addictions.

Diagnosis, Dual (Psychiatry)
Assistance Publique - Hôpitaux de Paris

Unknown

ACT™ Balloons Versus Artificial Urinary Sphincter (AMS800™) for the Treatment of Female Stress Urinary Incontinence (SU-ACT)

Urinary Incontinence

France
Amgen

Suspended

A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC

Small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
ArmaGen, Inc

Completed

Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I

Mucopolysaccharidosis I

Brazil
Miguel Monfort Montolio

Completed

Animal-Assisted Therapy in the Residential Treatment of Schizophrenia and Addictions

Diagnosis, Dual (Psychiatry)
ArmaGen, Inc

Completed

Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I

Mucopolysaccharidosis I

Brazil
Kathleen Ludwig

Available

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients With Relapsed or Refractory ALL or LL

Relapsed Childhood ALL | Relapsed Childhood Lymphoblastic Lymphoma

United States
Applied Molecular Transport

Completed

Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)

Ulcerative Colitis

Georgia, Netherlands, Poland, Ukraine
Amyndas Pharmaceuticals S.A.

Unknown

A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE) (SAVE)

Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)
Ohio State University Comprehensive Cancer Center

Recruiting

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Merrimack Pharmaceuticals

Terminated

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

Colorectal Cancer | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer

United States
Brii Biosciences, Inc.

Withdrawn

A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19

COVID-19

China
AbbVie

No longer available

Expanded Access to Navitoclax

Myelofibrosis | Lymphoblastic Lymphoma | Acute Lymphocytic Leukemia (ALL)

United States
AbbVie
Genentech, Inc.

Completed

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States, Australia
Amyndas Pharmaceuticals S.A.

Completed

A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis

Gingivitis

United States
The University of Hong Kong
The Hong Kong Jockey Club Charities Trust; Hong Kong Young Women's Christian... and other collaborators

Recruiting

Acceptance and Commitment Therapy and Exercise for Older Adults With Chronic Pain

Chronic Pain | Exercise | Older Adults | Acceptance and Commitment Therapy | Psychosocial Intervention | Art

Hong Kong
Yale University

Completed

A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

CTCL

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

Lupus Erythematosus

United States, Germany, Mexico, Puerto Rico
David Bushnell
VA Office of Research and Development

Completed

Combination Targeted Radiotherapy in Neuroendocrine Tumors

Neuroendocrine Tumors

United States
Groupe Francophone des Myelodysplasies
AbbVie

Recruiting

Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) (AVENHIR)

Chronic Myeloid Leukemia

France
AbbVie

Available

Expanded Access to Venetoclax

Multiple Myeloma | Non-Hodgkin's Lymphoma | Amyloidosis | Chronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Plasma Cell Leukemia
Fondazione Italiana Linfomi - ETS

Terminated

Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

T-Cell Lymphoma Relapsed | T-Cell Lymphoma Refractory

Italy
AbbVie

Completed

Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers

Healthy Volunteers

United States
Peter MacCallum Cancer Centre, Australia

Active, not recruiting

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) (AIM)

Mantle Cell Lymphoma

Australia
AbbVie

Completed

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). (VENICE II)

Chronic Lymphocytic Leukemia (CLL)

Argentina, Australia, Bulgaria, Hong Kong, Hungary, Mexico, New Zealand, Poland, Russian Federation, Taiwan

Search clinical trials for: AMT-191

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations